

Supplementary Materials

Table S1. CRIS checklist for reporting in-vitro studies based on previously guidelines *.

Section/topic	Checklist item	
Abstract	Item 1. Structured summary of trial design, methods, results, and conclusions	Yes
Introduction		
<i>Background and objectives</i>	Item 2a. Scientific background and explanation of rationale	Yes
	Item 2b. Specific objectives and/or hypotheses	Yes
Methods		
<i>Intervention</i>	Item 3. The intervention for each group, including how and when it was administered, with sufficient detail to enable replication	Yes
<i>Outcomes</i>	Item 4. Completely defined, pre-specified primary and secondary measures of outcome, including how and when they were assessed	Yes
<i>Sample size</i>	Item 5. How sample size was determined	Yes
<i>Randomization:</i>		
<i>Sequence generation</i>	Item 6. Method used to generate the random allocation sequence	Not applicable
<i>Allocation concealment mechanism</i>	Item 7. Mechanism used to implement the random allocation sequence (for example, sequentially numbered containers), describing any steps taken to conceal the sequence until intervention was assigned	Not applicable
<i>Implementation</i>	Item 8. Who generated the random allocation sequence, who enrolled teeth, and who assigned teeth to intervention	Not applicable
<i>Blinding</i>	Item 9. If done, who was blinded after assignment to intervention (for example, care providers, those assessing outcomes), and how	Not applicable
<i>Statistical methods</i>	Item 10. Statistical methods used to compare groups for primary and secondary outcomes	Yes
Results		
<i>Outcomes and estimation</i>	Item 11. For each primary and secondary outcome, results for each group, and the estimated size of the effect and its precision (for example 95% confidence interval)	Yes
Discussion		
<i>Limitations</i>	Item 12. Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	Yes
Other information		
<i>Funding</i>	Item 13. Sources of funding and other support (for example suppliers of drugs), role of funders	Yes
<i>Protocol</i>	Item 14. Where the full trial protocol can be accessed, if available	Yes

* <https://doi.org/10.1016/j.jebdp.2012.10.001> (accessed on 23 July 2022). * <https://pubmed.ncbi.nlm.nih.gov/25125839/> (accessed on 23 July 2022).